Loading...
Docoh

Centogene (CNTG)

CENTOGENE engages in diagnosis and research around rare diseases transforming real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. Its goal is to bring rationality to treatment decisions and to accelerate the development of new orphan drugs by using its extensive rare disease knowledge, including epidemiological and clinical data, as well as innovative biomarkers. CENTOGENE has developed a global proprietary rare disease platform based on its real-world data repository with over 3.6 billion weighted data points from approximately 595,000 patients representing over 120 different countries as of September 30, 2020. The Company's platform includes epidemiologic, phenotypic, and genetic data that reflects a global population, and also a biobank of these patients' blood samples. CENTOGENE believes this represents the only platform that comprehensively analyzes multi-level data to improve the understanding of rare hereditary diseases, which can aid in the identification of patients and improve its pharmaceutical partners' ability to bring orphan drugs to the market. As of September 30, 2020, the Company collaborated with over 40 pharmaceutical partners covering over 45 different rare diseases.

CNTG stock data

Calendar

31 Mar 22
26 Jun 22
31 Dec 22
Quarter (USD) Dec 21 Dec 20 Dec 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
38.4% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 10 19 -47.4%
Opened positions 0 0
Closed positions 9 6 +50.0%
Increased positions 3 6 -50.0%
Reduced positions 5 8 -37.5%
13F shares Current Prev Q Change
Total value 69.93M 87.64M -20.2%
Total shares 8.49M 8.81M -3.6%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners Shares Value Change
DPE Deutsche Private Equity Gesellschaft mbH 6.04M $57.1M 0.0%
Platinum Investment Management 2.28M $11.91M +18.4%
Acadian Asset Management 70.73K $366K +16.2%
Renaissance Technologies 48.47K $253K -13.8%
BLK Blackrock 21.42K $111K -5.0%
NTRS Northern Trust 13.45K $70K -1.2%
Geode Capital Management 11.16K $57K -0.1%
JPM JPMorgan Chase & Co. 7.29K $37K +1026.6%
Meeder Asset Management 5.17K $27K -0.6%
BAC Bank Of America 309 $1K 0.0%
Largest transactions Shares Bought/sold Change
Millennium Management 0 -498.19K EXIT
Platinum Investment Management 2.28M +354.07K +18.4%
WFC Wells Fargo & Co. 0 -108.74K EXIT
Ergoteles 0 -38.66K EXIT
HRT Financial 0 -17.81K EXIT
MS Morgan Stanley 0 -14.51K EXIT
Acadian Asset Management 70.73K +9.85K +16.2%
Renaissance Technologies 48.47K -7.73K -13.8%
JPM JPMorgan Chase & Co. 7.29K +6.64K +1026.6%
Optiver Holding B.V. 0 -2K EXIT

Financial report summary

?
Competition
InvitaeFulgent Genetics

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
Proxies
No filings